Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/enhanced-american-college-of-cardiology-american-heart-association-2qf7wjvepa
References (65)
-
J. Brush (2018)
Is the Cognitive Cardiologist Obsolete?JAMA cardiology, 3 8
-
Writing Members, B. Maron, W. McKenna, G. Danielson, L. Kappenberger, H. Kuhn, C. Seidman, P. Shah, William III, P. Spirito, F. Cate, E. Wigle, J. Abrams, E. Bates, B. Brodie, P. Danias, G. Gregoratos, M. Hlatky, J. Hochman, S. Kaul, R. Lichtenberg, J. Lindner, Robert 'rourke, G. Pohost, R. Schofield, C. Tracy, W. Winters, Werner Klein, S. Priori, Ángeles Alonso-García, C. Blomström-Lundqvist, G. Backer, J. Deckers, M. Flather, J. Hradec, A. Oto, A. Parkhomenko, S. Silber, A. Torbicki, Maron Bj, Mckenna Wj, Danielson Gk, Kappenberger Lj, Kuhn Hj, Seidman Ce, Shah Pm, Spencer Wh, Spirito P, Cate Fj, Wigle Ed, R. Vogel (2003)
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice GJournal of the American College of Cardiology, 42 9
-
Vriesendorp (2015)
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.Circ Arrhythm Electrophysiol, 8
-
E. Rowin, B. Maron, A. Chokshi, M. Maron (2018)
Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any agePacing and Clinical Electrophysiology, 41
-
A. Grace (2015)
Prophylactic implantable defibrillators for hypertrophic cardiomyopathy: disarray in the era of precision medicine.Circulation. Arrhythmia and electrophysiology, 8 4
-
B. Maron, P. Spirito, W. Shen, Tammy Haas, Francesco Formisano, M. Link, A. Epstein, A. Almquist, J. Daubert, T. Lawrenz, G. Boriani, N. Estes, S. Favale, M. Piccininno, S. Winters, M. Santini, S. Betocchi, F. Arribas, M. Sherrid, G. Buja, C. Semsarian, P. Bruzzi (2007)
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA, 298 4
-
A. Moss, H. Greenberg, R. Case, W. Zareba, W. Hall, Mary Brown, J. Daubert, S. McNitt, M. Andrews, Adam Elkin (2004)
Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted DefibrillatorCirculation, 110
-
P. Elliott, J. Blanes, N. Mahon, J. Poloniecki, W. McKenna (2001)
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathyThe Lancet, 357
-
P. Elliott, J. Poloniecki, S. Dickie, Sanjay Sharma, L. Monserrat, A. Varnava, N. Mahon, W. McKenna (2000)
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.Journal of the American College of Cardiology, 36 7
-
B. Gersh, B. Maron, R. Bonow, J. Dearani, M. Fifer, M. Link, S. Naidu, R. Nishimura, S. Ommen, H. Rakowski, C. Seidman, J. Towbin, J. Udelson, C. Yancy (2011)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation, 124
-
C. O’Mahony, M. Tomé-Esteban, P. Lambiase, A. Pantazis, S. Dickie, W. McKenna, P. Elliott (2013)
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathyHeart, 99
-
B. Maron (2018)
Clinical Course and Management of Hypertrophic CardiomyopathyThe New England Journal of Medicine, 379
-
Carolyn Ho, M. Link (2018)
Predicting the Future in Hypertrophic CardiomyopathyCirculation, 137
-
Al-Khatib (2018)
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart Rhythm, 15
-
L. Monserrat, P. Elliott, J. Gimeno, Sanjay Sharma, M. Penas-Lado, W. McKenna (2003)
Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.Journal of the American College of Cardiology, 42 5
-
I. Olivotto, B. Maron, A. Montereggi, F. Mazzuoli, A. Dolara, F. Cecchi (2016)
Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy -
S. Al‐Khatib, William Stevenson, Michael Ackerman, William Bryant, D. Callans, Anne Curtis, Barbara Deal, T. Dickfeld, Michael Field, G. Fonarow, Anne Gillis, Christopher Granger, Stephen Hammill, M. Hlatky, J. Joglar, G. Kay, Daniel Matlock, R. Myerburg, Richard Page (2017)
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Journal of the American College of Cardiology, 72 14
-
B. Maron, S. Casey, I. Olivotto, M. Sherrid, C. Semsarian, C. Autore, Aisha Ahmed, G. Boriani, P. Francia, S. Winters, M. Giudici, Anna Koulova, R. Garberich, E. Rowin, S. Sears, M. Maron, P. Spirito (2018)
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-DefibrillatorsCirculation: Arrhythmia and Electrophysiology, 11
-
Weijia Wang, Zhesi Lian, E. Rowin, B. Maron, M. Maron, M. Link (2017)
Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic CardiomyopathyCirculation: Arrhythmia and Electrophysiology, 10
-
Raymond Chan, B. Maron, I. Olivotto, M. Pencina, G. Assenza, Tammy Haas, J. Lesser, C. Gruner, A. Crean, H. Rakowski, J. Udelson, E. Rowin, M. Lombardi, F. Cecchi, B. Tomberli, P. Spirito, Francesco Formisano, E. Biagini, C. Rapezzi, C. Cecco, C. Autore, E. Cook, S. Hong, C. Gibson, W. Manning, E. Appelbaum, M. Maron (2014)
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic CardiomyopathyCirculation, 130
-
E. Rowin, M. Maron, R. Chan, A. Hausvater, Wendy Wang, H. Rastegar, B. Maron (2017)
Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy.The American journal of cardiology, 120 12
-
V. Fuster (2017)
The Proliferation of Scoring Systems: Trying to Keep Our Heads Out of The Clouds.Journal of the American College of Cardiology, 69 12
-
Olivotto (1999)
Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy.J Am Coll Cardiol, 33
-
B. Maron, E. Rowin, S. Casey, Tammy Haas, R. Chan, J. Udelson, R. Garberich, J. Lesser, E. Appelbaum, W. Manning, M. Maron (2013)
Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of AgeCirculation, 127
-
A. Schinkel, P. Vriesendorp, E. Sijbrands, L. Jordaens, F. Cate, M. Michels (2012)
Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy: Systematic Review and Meta-AnalysisCirculation: Heart Failure, 5
-
Maron (2008)
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.Circulation, 118
-
C. O’Mahony, F. Jichi, S. Ommen, I. Christiaans, E. Arbustini, P. García-Pavía, F. Cecchi, I. Olivotto, H. Kitaoka, I. Gotsman, G. Carr-White, J. Mogensen, L. Antoniades, S. Mohiddin, M. Maurer, H. Tang, J. Geske, Konstantinos Siontis, K. Mahmoud, A. Vermeer, A. Wilde, V. Favalli, O. Guttmann, M. Gallego-Delgado, F. Domínguez, I. Tanini, T. Kubo, A. Keren, T. Bueser, Sarah Waters, I. Issa, J. Malcolmson, T. Burns, N. Sekhri, Christopher Hoeger, R. Omar, P. Elliott (2017)
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)Circulation, 137
-
B. Maron, M. Maron, E. Rowin (2017)
Perspectives on the Overall Risks of Living With Hypertrophic CardiomyopathyCirculation, 135
-
B. Maron, E. Rowin, S. Casey, J. Lesser, R. Garberich, D. McGriff, M. Maron (2016)
Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management StrategiesCirculation, 133
-
B. Maron, P. Spirito, M. Ackerman, S. Casey, C. Semsarian, N. Estes, K. Shannon, E. Ashley, S. Day, G. Pacileo, Francesco Formisano, E. Devoto, A. Anastasakis, J. Bos, A. Woo, C. Autore, R. Pass, G. Boriani, R. Garberich, A. Almquist, M. Russell, L. Boni, S. Berger, M. Maron, M. Link (2013)
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.Journal of the American College of Cardiology, 61 14
-
A. Woo, D. Monakier, L. Harris, Ann Hill, P. Shah, E. Wigle, H. Rakowski, Evelyn Rozenblyum, D. Cameron (2007)
Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathyHeart, 93
-
N. Sadoul, K. Prasad, P. Elliott, Soma Bannerjee, M. Frenneaux, W. McKenna (1997)
Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy.Circulation, 96 9
-
B. Maron, E. Rowin, S. Casey, M. Maron (2016)
How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice.JAMA cardiology, 1 1
-
P. Spirito, P. Bellone, K. Harris, P. Bernabò, P. Bruzzi, B. Maron (2000)
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.The New England journal of medicine, 342 24
-
J. Udelson (2019)
Evaluating and Reducing the Risk of Sudden Death in Hypertrophic Cardiomyopathy.Circulation
-
P. Spirito, C. Autore, Francesco Formisano, G. Assenza, E. Biagini, Tammy Haas, S. Bongioanni, C. Semsarian, E. Devoto, B. Musumeci, Francesco Lai, L. Yeates, M. Conte, C. Rapezzi, L. Boni, B. Maron (2014)
Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors.The American journal of cardiology, 113 9
-
Kevin Leong, J. Chow, F. Ng, E. Falaschetti, N. Qureshi, M. Koa‐Wing, N. Linton, Z. Whinnett, D. Lefroy, D. Davies, P. Lim, N. Peters, P. Kanagaratnam, A. Varnava (2018)
Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic CardiomyopathyThe American Journal of Cardiology, 121
-
Wang (2017)
Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy.Circ Arrhythm Electrophysiol, 10
-
B. Maron, M. Maron (2016)
Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.Heart rhythm, 13 5
-
G. Bardy, Kerry Lee, D. Mark, J. Poole, D. Packer, R. Boineau, M. Domanski, C. Troutman, Jill Anderson, G. Johnson, S. McNulty, N. Clapp-Channing, L. Davidson-Ray, Elizabeth Fraulo, D. Fishbein, R. Luceri, J. Ip (2005)
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.The New England journal of medicine, 352 3
-
E. Rowin, B. Maron, Tammy Haas, R. Garberich, Weijia Wang, M. Link, M. Maron (2017)
Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.Journal of the American College of Cardiology, 69 7
-
W. Adkisson, B. Krishnan, D. Benditt (2017)
Syncope and Risk of Sudden Death -
I. Christiaans, K. Engelen, I. Langen, E. Birnie, G. Bonsel, P. Elliott, A. Wilde (2010)
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 12 3
-
A. Weissler-Snir, A. Adler, L. Williams, C. Gruner, H. Rakowski (2016)
Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.European heart journal, 38 22
-
C. O’Mahony, F. Jichi, M. Pavlou, L. Monserrat, A. Anastasakis, C. Rapezzi, E. Biagini, J. Gimeno, G. Limongelli, W. McKenna, R. Omar, P. Elliott (2014)
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).European heart journal, 35 30
-
Maron (2018)
Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators.Circ Arrhythm Electrophysiol, 11
-
M. Maron, J. Finley, J. Udelson (2009)
Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy”Circulation, 119
-
B. Maron, S. Casey, R. Chan, R. Garberich, E. Rowin, M. Maron (2015)
Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.The American journal of cardiology, 116 5
-
Schinkel (2012)
Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.Circ Heart Fail, 5
-
E. Rowin, B. Maron, Patrick Abt, M. Kiernan, A. Vest, F. Costantino, M. Maron, D. DeNofrio (2018)
Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy.The American journal of cardiology, 121 8
-
B. Maron, W. Shen, M. Link, Andrew Epstein, A. Almquist, J. Daubert, G. Bardy, S. Favale, R. Rea, G. Boriani, N. Estes, P. Spirito, S. Casey, M. Stanton, S. Betocchi (2000)
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.The New England journal of medicine, 342 6
-
P. Vriesendorp, A. Schinkel, M. Liebregts, D. Theuns, J. Cleemput, F. Cate, R. Willems, M. Michels (2015)
Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic CardiomyopathyCirculation: Arrhythmia and Electrophysiology, 8
-
P. Spirito, C. Autore, C. Rapezzi, P. Bernabò, R. Badagliacca, M. Maron, S. Bongioanni, F. Coccolo, N. Estes, C. Barillà, E. Biagini, G. Quarta, Maria Conte, P. Bruzzi, Barry Maron (2009)
Syncope and Risk of Sudden Death in Hypertrophic CardiomyopathyCirculation, 119
-
B. Maron, R. Nishimura, M. Maron (2017)
Shared decision-making in HCMNature Reviews Cardiology, 14
-
B. Maron, S. Ommen, C. Semsarian, P. Spirito, I. Olivotto, M. Maron (2014)
Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.Journal of the American College of Cardiology, 64 1
-
B. Maron, E. Rowin, S. Casey, M. Link, J. Lesser, R. Chan, R. Garberich, J. Udelson, M. Maron (2015)
Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.Journal of the American College of Cardiology, 65 18
-
E. Steyerberg, Y. Vergouwe (2014)
Towards better clinical prediction models: seven steps for development and an ABCD for validation.European heart journal, 35 29
-
Joseph Germano, M. Reynolds, V. Essebag, M. Josephson (2006)
Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?The American journal of cardiology, 97 8
-
J. Bos, B. Maron, M. Ackerman, Tammy Haas, P. Sorajja, R. Nishimura, B. Gersh, S. Ommen (2010)
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.The American journal of cardiology, 106 10
-
P. Vriesendorp, A. Schinkel, J. Cleemput, R. Willems, L. Jordaens, D. Theuns, M. Slegtenhorst, T. Ravel, F. Cate, M. Michels (2013)
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.American heart journal, 166 3
-
B. Maron (2016)
Saving Lives One at a Time.JAMA cardiology, 1 4
-
F. Streitner, Thomas Herrmann, J. Kuschyk, S. Lang, C. Doesch, T. Papavassiliu, Ines Streitner, C. Veltmann, D. Haghi, M. Borggrefe (2013)
Impact of Shocks on Mortality in Patients with Ischemic or Dilated Cardiomyopathy and Defibrillators Implanted for Primary PreventionPLoS ONE, 8
-
O. Watkinson, P. Elliott (2015)
A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy.The Canadian journal of cardiology, 31 11
-
T. Kiernan, Peggy Weivoda, V. Somers, S. Ommen, B. Gersh (2008)
Circadian Rhythm of Appropriate Implantable Cardioverter Defibrillator Discharges in Patients with Hypertrophic CardiomyopathyPacing and Clinical Electrophysiology, 31
-
Perry Elliott, A. Anastasakis, Michael Borger, Martin Borggrefe, Franco Cecchi, Philippe Charron, A. Hagège, Antoine Lafont, Giuseppe Limongelli, Heiko Mahrholdt, William McKenna, Jens Mogensen, Petros Nihoyannopoulos, Stefano Nistri, Petronella Pieper, Burkert Pieske, Claudio Rapezzi, Frans Rutten, Christoph Tillmanns, Hugh Watkins (2014)
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).European heart journal, 35 39
- Publisher
- American Medical Association
- Copyright
- Copyright 2019 American Medical Association. All Rights Reserved.
- ISSN
- 2380-6583
- eISSN
- 2380-6591
- DOI
- 10.1001/jamacardio.2019.1391
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionIs it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? FindingsIn this cohort study of 2094 patients with HCM, ICD decision making was prospectively assessed based on conventional major risk markers derived from the literature and enhanced from 2011 American College of Cardiology/American Heart Association guidelines over a 17-year experience at a single HCM center. Rates of appropriate ICD therapy terminating potentially lethal ventricular tachyarrhythmias exceeded SCDs in patients without ICDs by almost 50-fold. MeaningA prospective individual risk factor strategy predicted SCD events in nearly all at-risk patients with HCM, resulting in prophylactically implanted ICDs that prevented arrhythmic SCD events.
Journal
JAMA Cardiology – American Medical Association
Published: Jul 22, 2019